Hyperthermia enhances CTL cross-priming
/in Hyperthermia, International Publications /von 2006-02-15 / J. Immunol. 2006 Feb;176(4):2134-41Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA
/in Hepatocellular Carcinoma, International Publications /von 2006-02-10 / Cell. Immunol. 2005 Nov;238(1):61-6Therapeutic cancer vaccines
/in International Publications, Prostate Cancer /von 2006-02-07 / Curr. Opin. Immunol. 2006 Apr;18(2):201-5Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12
/in Glioblastoma, International Publications /von 2006-02-04 / Cancer Immunol. Immunother. 2006 Nov;55(11):1309-19Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation
/in Chronic Leukemia, International Publications /von 2006-02-03 / J. Leukoc. Biol. 2006 Apr;79(4):747-56Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost
/in HIV/AIDS, International Publications /von 2006-02-02 / Clin. Immunol. 2006 Apr;119(1):32-7Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines
/in International Publications, Ovarian Cancer /von 2006-02-01 / Cancer Gene Ther. 2006 Feb;13(2):182-93Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
/in Dendritic Cells, International Publications, SCLC /von 2006-02-01 / Clin. Cancer Res. 2006 Feb;12(3 Pt 1):878-87A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
/in International Publications, Newcastle Disease Virus /von 2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-67
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution